These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 16595597)

  • 1. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
    Sesti G; Laratta E; Cardellini M; Andreozzi F; Del Guerra S; Irace C; Gnasso A; Grupillo M; Lauro R; Hribal ML; Perticone F; Marchetti P
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2334-9. PubMed ID: 16595597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.
    Javorsky M; Klimcakova L; Schroner Z; Zidzik J; Babjakova E; Fabianova M; Kozarova M; Tkacova R; Salagovic J; Tkac I
    Eur J Intern Med; 2012 Apr; 23(3):245-9. PubMed ID: 22385882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
    Holstein A; Hahn M; Stumvoll M; Kovacs P
    Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
    Sesti G; Marini MA; Cardellini M; Sciacqua A; Frontoni S; Andreozzi F; Irace C; Lauro D; Gnasso A; Federici M; Perticone F; Lauro R
    Diabetes Care; 2004 Jun; 27(6):1394-8. PubMed ID: 15161794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients.
    Li Q; Chen M; Zhang R; Jiang F; Wang J; Zhou J; Bao Y; Hu C; Jia W
    Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):748-54. PubMed ID: 25115353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes.
    Gloyn AL; Weedon MN; Owen KR; Turner MJ; Knight BA; Hitman G; Walker M; Levy JC; Sampson M; Halford S; McCarthy MI; Hattersley AT; Frayling TM
    Diabetes; 2003 Feb; 52(2):568-72. PubMed ID: 12540637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
    Lau E; Correia C; Freitas P; Nogueira C; Costa M; Saavedra A; Costa C; Carvalho D; Fontoura M
    Arch Endocrinol Metab; 2015 Dec; 59(6):559-61. PubMed ID: 26331221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The E23K variant in the Kir6.2 subunit of the ATP-sensitive K+ channel does not augment impaired glucose tolerance in Caribbean subjects with a family history of type 2 diabetes.
    Ezenwaka C; Kalloo R; Uhlig M; Schwenk R; Eckel J
    J Endocrinol; 2005 Jun; 185(3):439-44. PubMed ID: 15930170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.
    Ragia G; Tavridou A; Petridis I; Manolopoulos VG
    Diabetes Res Clin Pract; 2012 Oct; 98(1):119-24. PubMed ID: 22591706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel.
    Hamming KS; Soliman D; Matemisz LC; Niazi O; Lang Y; Gloyn AL; Light PE
    Diabetes; 2009 Oct; 58(10):2419-24. PubMed ID: 19587354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal diabetes caused by a homozygous KCNJ11 mutation demonstrates that tiny changes in ATP sensitivity markedly affect diabetes risk.
    Vedovato N; Cliff E; Proks P; Poovazhagi V; Flanagan SE; Ellard S; Hattersley AT; Ashcroft FM
    Diabetologia; 2016 Jul; 59(7):1430-1436. PubMed ID: 27118464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.
    Song J; Yang Y; Mauvais-Jarvis F; Wang YP; Niu T
    BMC Med Genet; 2017 Jun; 18(1):64. PubMed ID: 28587604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy.
    Sagen JV; Raeder H; Hathout E; Shehadeh N; Gudmundsson K; Baevre H; Abuelo D; Phornphutkul C; Molnes J; Bell GI; Gloyn AL; Hattersley AT; Molven A; Søvik O; Njølstad PR
    Diabetes; 2004 Oct; 53(10):2713-8. PubMed ID: 15448106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes.
    Nielsen EM; Hansen L; Carstensen B; Echwald SM; Drivsholm T; Glümer C; Thorsteinsson B; Borch-Johnsen K; Hansen T; Pedersen O
    Diabetes; 2003 Feb; 52(2):573-7. PubMed ID: 12540638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Search for Pharmacoepigenetic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment.
    Karaglani M; Ragia G; Panagopoulou M; Balgkouranidou I; Nena E; Kolios G; Papanas N; Manolopoulos VG; Chatzaki E
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):226-233. PubMed ID: 29396966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy.
    Proks P; Girard C; Baevre H; Njølstad PR; Ashcroft FM
    Diabetes; 2006 Jun; 55(6):1731-7. PubMed ID: 16731836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.
    Flechtner I; de Lonlay P; Polak M
    Diabetes Metab; 2006 Dec; 32(6):569-80. PubMed ID: 17296510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program.
    Florez JC; Jablonski KA; Kahn SE; Franks PW; Dabelea D; Hamman RF; Knowler WC; Nathan DM; Altshuler D
    Diabetes; 2007 Feb; 56(2):531-6. PubMed ID: 17259403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
    Bowman P; Sulen Å; Barbetti F; Beltrand J; Svalastoga P; Codner E; Tessmann EH; Juliusson PB; Skrivarhaug T; Pearson ER; Flanagan SE; Babiker T; Thomas NJ; Shepherd MH; Ellard S; Klimes I; Szopa M; Polak M; Iafusco D; Hattersley AT; Njølstad PR;
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.
    Al-Mahdi M; Al Mutair A; Al Balwi M; Hussain K
    Ann Saudi Med; 2010; 30(2):162-4. PubMed ID: 20220270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.